Record Sales and Transition to Profitability
Aurora Spine reported sales of $4.8 million for Q3 2024, marking the fourth consecutive quarter of over $4 million in sales, with a 21% increase compared to Q3 2023. The company achieved a net income of $71,000, transitioning from a net loss of $248,000 in Q3 2023.
Strong Performance of SiLO TFX and ZIP 51
SiLO TFX sales grew by 35% from Q2 2024 to Q3 2024, and ZIP 51 sales doubled in 2024 compared to 2023. SiLO TFX accounted for 48% of all sales, reflecting robust demand in the pain management sector.
Gross Margin Improvement
Gross margin improved to 60% in Q3 2024, up from 59.7% in the same period last year, driven by increased sales of proprietary products with higher profitability.
Positive Operating Cash Flow
The company generated $519,000 in operating cash flow, reflecting strong operational performance and efficient working capital management.
Successful Expansion into New Markets
The company expanded its sales force and targeted underserved markets, contributing to significant sales growth and improved profitability.